1. Home
  2. Approved trials
  3. » فارسی

The comparative evaluation of the effect of sublingual and cervical misoprostol on the duration of abortion in patients candidate for abortion in the first trimester of pregnancy

Protocol summary

Study aim
The Determination of the effect of sublingual and cervical misoprostol on the the abortion rate and duration of abortion in the first trimester of pregnancy in patients candidate for abortion
Design
Clinical trials , with parallel groups, randomized
Settings and conduct
This study is performed in Qazvin University of Medical Sciences. In this study, all pregnant women with a gestational age of 1 to 12 weeks who are candidates for legal abortion and referred to Kowsar and Mehregan hospitals in Qazvin are examined and included in the study. This study is performed as a randomized single-blind clinical trial (participant in the project). Data collection is completed by the questioner which is done through a checklist. The sample size was 200 people. If they meet the inclusion criteria,enter the study and are randomly divided into two equal groups a and b.
Participants/Inclusion and exclusion criteria
Inclusion Criteria : Unifetal pregnancy , Missed abortion , Fetal malformations , Blighted ovum,Trisomies ,Gestational age ( 12 weeks and less than 12 weeks ) ;Exclusion Criteria : Rupture of membrane , History of cesarean section more than once, Multifetal pregnancy, History of allergy to misoprostol and prostaglandins , Contraindications of prostaglandin use ( like heart disease, kidney disease, history of seizures and hypotension )
Intervention groups
At the beginning , patients of group A will receive 400 micrograms of sublingual misoprostol along with cervical placebo and , patients of group b will receive 400 micrograms of wet ted cervical misoprostol along with sublingual placebo, and then the dose is repeated every 4 hours until the abortion, and the maximum duration of administration of the drug will be up to 48 hours.
Main outcome variables
The time interval between induction of abortion and excretion of pregnancy products

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20200127046280N1
Registration date: 2020-10-16, 1399/07/25
Registration timing: prospective

Last update: 2020-10-16, 1399/07/25
Update count: 0
Registration date
2020-10-16, 1399/07/25
Registrant information
Name
Amirhossein Gholamlou
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 6655 6253
Email address
a.gholamlou@qums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-10-22, 1399/08/01
Expected recruitment end date
2021-03-19, 1399/12/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The comparative evaluation of the effect of sublingual and cervical misoprostol on the duration of abortion in patients candidate for abortion in the first trimester of pregnancy
Public title
The comparative evaluation of the effect of sublingual and cervical misoprostol on first trimester abortion
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Unifetal pregnancy Missed abortion Fetal malformations blighted ovum Trisomies Gestational age (12 weeks and less than 12 weeks )
Exclusion criteria:
Rupture of membrane History of cesarean section more than once Multifetal pregnancy History of allergy to misoprostol and prostaglandins Contraindications of prostaglandin use ( like heart disease, kidney disease, history of seizures and hypotension )
Age
From 16 years old to 45 years old
Gender
Female
Phase
2-3
Groups that have been masked
  • Participant
Sample size
Target sample size: 200
Randomization (investigator's opinion)
Randomized
Randomization description
Patients who meet the inclusion criteria are divided into two intervention groups using simple randomization method.The randomization method used in this study is the use of a table of random numbers.Random number table is a set of numbers that is generated without a specific pattern or order and they generated randomly and they are formed in a table.In first the direction of reading the numbers was specified.To read the numbers, random numbers are read from the left side of the table, then even numbers extracted from the table are allocated to intervention group a and odd numbers extracted from the table are allocated to intervention group b.
Blinding (investigator's opinion)
Single blinded
Blinding description
Participants are unaware of treatment allocation and are divided into groups a and b. Group a receives sublingual misoprostol with cervical placebo and group b receives cervical misoprostol with sublingual placebo. Finally, the results of the work are filled by the midwife of the ward, using the questionnaire form and provided to the researcher.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Qazvin University Of Medical Science
Street address
No 4, mavedat ave, shahid beheshti blvd
City
Qazvin
Province
Qazvin
Postal code
1391134156
Approval date
2020-01-25, 1398/11/05
Ethics committee reference number
IR.QUMS.REC.1398.280

Health conditions studied

1

Description of health condition studied
Abortion
ICD-10 code
O02.1
ICD-10 code description
Missed abortion

Primary outcomes

1

Description
The time interval between induction of abortion and excretion of pregnancy products
Timepoint
After intervention and then every one hour
Method of measurement
clock

2

Description
Nausea (drug side effects)
Timepoint
After intervention and then every one hour
Method of measurement
Clinical examination and questioning of the patient

3

Description
Vomiting (drug side effects)
Timepoint
After intervention and then every one hour
Method of measurement
Clinical examination and questioning of the patient

4

Description
Fever (drug side effects)
Timepoint
After intervention and then every one hour
Method of measurement
Thermometer

5

Description
Diarrhea (drug side effects)
Timepoint
After intervention and then every one hour
Method of measurement
Clinical examination and questioning of the patient

6

Description
Headache (drug side effects)
Timepoint
After intervention and then every one hour
Method of measurement
Clinical examination and questioning of the patient

7

Description
abortion type (Complete or incomplete)
Timepoint
After intervention and then every one hour
Method of measurement
Clinical examination and questioning of the patient

Secondary outcomes

empty

Intervention groups

1

Description
First intervention group (group a): This group will receive 400 mcg of sublingual misoprostol from the brand (Cytotec, Searle, England) along with cervical placebo and then the mentioned dose will be repeated every 4 hours until the abortion.The maximum duration of drug administration will be up to 48 hours.
Category
Treatment - Drugs

2

Description
Intervention group 2 (group b): This group will receive 400 mcg of cervical misoprostol from brand (Cytotec, Searle, England) moistened with a few drops of distilled water along with sublingual placebo and then the mentioned dose is repeated every 4 hours until abortion. The maximum duration of drug administration will be up to 48 hours.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Kowsar hospital
Full name of responsible person
Masoumeh Dadashaliha
Street address
Kowsar Hospital, Kowsar Alley, next to the electricity office, Taleghani St
City
Qazvin
Province
Qazvin
Postal code
3415613176
Phone
+98 28 3323 6376
Fax
+98 28 3323 6376
Email
dadashaliham@yahoo.com
Web page address
http://www.qums.ac.ir/Portal/Home/

2

Recruitment center
Name of recruitment center
Mehregan hospital
Full name of responsible person
Masoumeh Dadashaliha
Street address
Mehregan Hospital, next to Dialysis Center, Ferdowsi St.
City
Qazvin
Province
Qazvin
Postal code
3415613176
Phone
+98 28 3336 5160
Fax
+98 28 3336 5160
Email
dadashaliham@yahoo.com
Web page address
http://www.qums.ac.ir/Portal/Home/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Qazvin University of Medical Sciences
Full name of responsible person
Dr. Mohammad Mahdi Emamjomeh
Street address
Qazvin University Of medical Science ,Shahid Bahonar Blvd.
City
Qazvin
Province
Qazvin
Postal code
5981134197
Phone
+98 28 3333 6001
Fax
+98 28 3333 6001
Email
medicine@qums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Qazvin University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Qazvin University of Medical Sciences
Full name of responsible person
Masoumeh Dadashaliha
Position
Associate Professor
Latest degree
Specialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
No. 2, Bahar Doctors Building ,East Bouali St.
City
Qazvin
Province
Qazvin
Postal code
3491658875
Phone
+98 28 3322 9304
Email
dadashaliham@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Qazvin University of Medical Sciences
Full name of responsible person
Masoumeh Dadashaliha
Position
Associate Professor
Latest degree
Specialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
No. 2, Bahar Doctors Building ,East Bouali St.
City
Qazvin
Province
Qazvin
Postal code
3491658875
Phone
+98 28 3322 9304
Email
dadashaliham@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Qazvin University of Medical Sciences
Full name of responsible person
Masoumeh dadashaliha
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
No. 2, Bahar Doctors Building ,East Bouali St.
City
Qazvin
Province
Qazvin
Postal code
3491658875
Phone
+98 28 3322 9304
Email
dadashaliham@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Not applicable
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
A part of the data, such as information about the main outcome, can be shared.
When the data will become available and for how long
Access period starts 6 months after publishing the results.
To whom data/document is available
It will be available only to researchers working in academic and scientific institutions.
Under which criteria data/document could be used
If another similar clinical trial is performed
From where data/document is obtainable
Email
What processes are involved for a request to access data/document
After Receiving E-mail And Proposal And Ensuring That Information Is Not Misused
Comments
Loading...